VEGFC抗体,Rabbit Polyclonal VEGFC Antibody
  • VEGFC抗体,Rabbit Polyclonal VEGFC Antibody
  • VEGFC抗体,Rabbit Polyclonal VEGFC Antibody
  • VEGFC抗体,Rabbit Polyclonal VEGFC Antibody

VEGFC抗体

价格 询价
包装 20μl 50μl 100μl
最小起订量 1μl
发货地 湖北
更新日期 2025-05-12
QQ交谈 微信洽谈

产品详情

中文名称:VEGFC抗体英文名称:Rabbit Polyclonal VEGFC Antibody
品牌: 艾普蒂产地: 武汉
保存条件: Stored at -20°C for 2538 year. Avoid repeated freeze / thaw cycles.产品类别: 抗体
重组: 应用: WB: IHC-P: IHC-F: ICC/IF: IP:FC:ChIP: ELISA
种属反应性: Human,Mouse,Rat 宿主: Rabbit
偶联物: 靶点: VEGFC
2025-05-12 VEGFC抗体 Rabbit Polyclonal VEGFC Antibody 20μl/RMB;50μl/RMB;100μl/RMB 艾普蒂 武汉 Stored at -20°C for 2538 year. Avoid repeated freeze / thaw cycles. 抗体

验证与应用

应用及物种
WB咨询技术 Human,Mouse,Rat
IF咨询技术 Human,Mouse,Rat
IHC1/10-1/50 Human,Mouse,Rat
ICC技术咨询 Human,Mouse,Rat
FCM咨询技术 Human,Mouse,Rat
Elisa1/1000-1/10000 Human,Mouse,Rat
   

产品详情

AliasesVRP, Flt4-L
WB Predicted band size46 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenSynthetic peptide of human VEGFC
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

  •  

     

       Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: 231 cells, Primary antibody: P03627(VEGFC Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    


  •  

     

       The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P03627(VEGFC Antibody) at dilution 1/5. (Original magnification: ×200)    


           

参考文献

以下是3篇关于VEGFC抗体的代表性文献,供参考:

---

1. **文献名称**:*Vascular endothelial growth factor C (VEGF-C) promotes tumor lymphangiogenesis and lymphatic metastasis*

**作者**:Stacker SA, et al.

**摘要**:该研究利用抗VEGFC抗体阻断小鼠模型中肿瘤相关淋巴管生成,证明VEGFC通过激活VEGFR-3信号通路促进肿瘤细胞经淋巴系统转移,为抗VEGFC抗体在抑制肿瘤转移中的应用提供了实验依据。

---

2. **文献名称**:*VEGF-C is a ligand for VEGFR-3 (Flt-4) in human endothelial cells and induces lymphangiogenesis in vivo*

**作者**:Joukov V, et al.

**摘要**:首次报道了VEGFC的克隆及其通过结合VEGFR-3受体促进淋巴管内皮细胞增殖的机制,研究中通过特异性抗体验证了VEGFC与受体的相互作用,奠定了VEGFC在淋巴管发育中的关键作用。

---

3. **文献名称**:*Therapeutic targeting of VEGF-C in metastatic cancer: Current status and future perspectives*

**作者**:Alitalo K, et al.

**摘要**:综述了VEGFC在肿瘤微环境中的功能及靶向治疗策略,总结了多种抗VEGFC抗体的临床前研究进展,包括抗体介导的信号阻断和联合免疫治疗的潜力。

---

如需更具体的研究方向(如抗体开发技术或临床实验),可进一步补充说明。

       

背景信息

Vascular endothelial growth factor C (VEGFC) is a key signaling protein involved in lymphangiogenesis (formation of lymphatic vessels) and angiogenesis (formation of blood vessels). It primarily binds to tyrosine kinase receptors VEGFR-3 (FLT4) and VEGFR-2 (KDR), activating downstream pathways that regulate endothelial cell proliferation, migration, and survival. VEGFC plays critical roles in embryonic development, tissue repair, and pathological conditions such as cancer metastasis and lymphedema. Dysregulation of VEGFC is linked to tumor-associated lymphatic spread and inflammatory diseases.

VEGFC antibodies are immunodetection tools or therapeutic agents designed to specifically target VEGFC or its receptors. In research, they are widely used to inhibit VEGFC activity in vitro and in vivo, helping to elucidate its biological functions and interactions. Common applications include blocking ligand-receptor binding in mechanistic studies, suppressing lymphangiogenesis in disease models, and detecting VEGFC expression via techniques like Western blot, immunohistochemistry (IHC), or ELISA. Therapeutically, anti-VEGFC monoclonal antibodies or receptor inhibitors are under investigation for cancers (to curb metastasis) and lymphatic disorders. Clinical trials explore their potential in combination with anti-VEGFA therapies to overcome resistance in anti-angiogenic treatments. However, challenges remain in optimizing specificity, delivery, and minimizing off-target effects. Recent advancements include humanized antibodies and bispecific designs targeting multiple angiogenic pathways.

       
关键字: VEGFC抗体;VEGFC;VEGFC Antibody;

公司简介

湖北瑞和宁生物科技有限公司研究创新能力, 拥有完整、科学、质量管理体系。并不断致力于技术创新,产品创新和管理创新,赢得了国内外广大用户的信任。
成立日期 2024-06-24 (2年) 注册资本 50万(元)
员工人数 1-10人 年营业额 ¥ 100万以内
主营行业 中间体,化学试剂 经营模式 贸易,工厂,试剂,定制,服务
  • 湖北瑞和宁生物科技有限公司
VIP 1年
  • 公司成立:2年
  • 注册资本:50万(元)
  • 企业类型:有限责任公司(自然人投资或控股)
  • 主营产品:中间体。试剂
  • 公司地址:江汉区
询盘

店内推荐

VEGFC抗体相关厂家报价

产品名称 价格   公司名称 报价日期
¥1950
VIP4年
上海沪震实业有限公司
2025-12-02
¥1600.00
VIP10年
北京索莱宝科技有限公司
2025-12-02
¥1800
VIP1年
费雪(杭州)医学研究有限公司
2025-11-24
内容声明:
以上所展示的信息由商家自行提供,内容的真实性、准确性和合法性由发布商家负责。 商家发布价格指该商品的参考价格,并非原价,该价格可能随着市场变化,或是由于您购买数量不同或所选规格不同而发生变化。最终成交价格,请咨询商家,以实际成交价格为准。请意识到互联网交易中的风险是客观存在的
主页 | 企业会员服务 | 广告业务 | 联系我们 | 旧版入口 | 中文MSDS | CAS Index | 常用化学品CAS列表 | 化工产品目录 | 新产品列表 |投诉中心
Copyright © 2008 ChemicalBook 京ICP备07040585号  京公海网安备110108000080号  All rights reserved.